Medibio building credentials to "scale" via appointment of healthcare & telehealth icon to Board of Directors
19.7.2017 15:00 | NASDAQ OMX
SYDNEY, Australia and MINNEAPOLIS, July 19, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a digital health company that has developed an objective testing system to assist in the screening, diagnosis and treatment effectiveness of depression, chronic stress and other mental health disorders, is pleased to announce the appointment of Dr Adam Darkins, MB, ChB., MPHM, M.D., FRCS to the Board of Directors as Deputy Chairman. Dr Darkins has unique experience in taking national and trans-national virtual care delivery systems to scale.
Medibio Board member and fellow physician, Dr Frank Prendergast, M.D. said, "Adam is a wonderful addition to the Medibio Board. He complements our team, drawing on a wealth of experience gained from the practice of medicine, health care management, and having built one of the world's largest, telehealth programs. His proven track-record in tackling one of the current greatest healthcare challenges - how to introduce transformational new technologies that demonstrably increase access to care and reduce its cost - is what makes him so unique. His creativity and rigour, in design, and continuing development, of innovative care systems will help guide Medibio to meet anticipated milestones in our growth trajectory as we transition from clinical validation to regulatory approval, and then commence broader implementations. Adam will help us to lay the strategic foundations for large-scale operations in the pre-eminent health care systems of the future."
Dr Darkins developed an extensive understanding of patient care, clinical processes, and outcomes measurement from his physician training at Manchester University Medical School, UK, and further training/accreditation as a neurosurgeon and researcher at UCLA. Studying public health medicine at the London School of Hygiene and Tropical Medicine, and pioneering shared patient decision-making programs at the King's Fund, London, grounded him in leading transformative change with a particular talent for safely and effectively taking long-established hospital-based practice into primary care, community care and non-traditional settings. Thereafter, already renowned for his ability to utilise new information and telecommunication technologies to empower patients, increase access to care and reduce cost, he gained widespread US and international recognition for his leadership of telehealth programs at the US Department of Veterans Affairs (VA). At VA he developed health informatics, telehealth and disease management technologies to enhance and extend care and case management. Together with his team, Dr Darkins created a capacity that delivered virtual services to more than 480,000 Veteran patients each year via 1.4 million episodes of care. On any given day, 83,000 Veteran patients were using home-telehealth technologies to live independently at home and avoid institutional care.
Dr Darkins comes to Medibio from Medtronic Plc where, as Vice President for Innovation and Strategic Partnerships for the Americas Region, he worked on using new payment models to transform health care. He has been permanently based in the USA since 1997. Dr Darkins serves on the editorial board of Telehealth and e-Health Journal; is a former Medical Director in London; co-founded a start-up telehealth company; and has both written, and spoken widely on how to address the challenges and find solutions in establishing large virtual health care networks that meet major health care priorities and deliver high volumes of patient consultation/care as their return on investment.
Medibio CEO, Jack Cosentino said, "We are thrilled to have Dr Darkins join the Medibio board. As a visionary leader in telehealth, he shares our Company's passion for solving one of the world's most significant health epidemics. His experience in building virtual care systems will help us to address the significant, yet under-recognised need for mental health support services globally. His expertise and achievements in the telehealth, IOT and patient care arenas, and leadership experience at organisations, including the UK National Health Service, U.S. Department of Veterans Affairs and Medtronic, complements an incredible team we are developing at Medibio, to exclusively focus on meeting this global need. We look forward to leveraging his knowledge, insights and relationships to heighten Mental Health awareness and identifying ways to reduce the stigma and isolation it can cause."
Medibio Chairman, Chris Indermaur stated, "We welcome Adam to the board of Medibio and value the addition of his leadership and passion to ours, as we collectively serve people with mental health conditions and seek to meet their aspirations for wellness and recovery."
|Further Information: www.medibio.com.au|
Medibio Shareholder Enquiries:
CEO and Managing Director Medibio Limited
T: +1 952 465 4787
Investor Relations Enquiries:
T: +61 (0)412 036 231
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a digital health company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilises patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence-based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Medibio was founded in Perth, Australia with offices located in Melbourne (VIC), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd (ASX) and trades on the OTCQB Venture Market. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com and www.asx.com.au.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
ATTO ThunderLink® enables VMware® ESXi(TM) for Mac Pro®24.8.2017 10:00 | Pressmeddelande
AMHERST, N.Y., Aug. 24, 2017 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for nearly 30 years, today is proud to announce their 16Gb and 8Gb Fibre Channel ThunderLink® Thunderbolt(TM) devices have achieved VMware Ready(TM) status for ESXi(TM). ATTO ThunderLink devices are the only purpose built Thunderbolt product designed to connect virtualized Mac hardware to 16Gb and 8Gb Fibre Channel storage solutions within VMware® VSphere environments. This provides a new and efficient solution for Apple technologies application development and testing environments, virtual desktop infrastructure and cloud hosting or shared private cloud. "By utilizing an ATTO ThunderLink in a VMware environment users can now take advantage of a one of a kind solution to bring virtualized Macs into test and development environments," said Tom Kolniak, Senior Director of
Karolinska Development - Delårsrapport för januari - juni 2017, inbjudan till telefonkonferens och webbpresentation24.8.2017 08:00 | Pressmeddelande
STOCKHOLM den 24 augusti 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) kommer att offentliggöra delårsrapporten för januari - juni 2017 efter att marknaden har stängt den 29 augusti 2017. Bolaget kommer även att hålla en telefonkonferens och webbpresentation den 30 augusti klockan 14.00 CEST. Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start: Från Sverige: +46 (0) 8 505 564 74 Från USA: +1 855 753 22 30 Från Storbritannien: +44 (0) 20 336 453 74 Webbpresentationen kan samtidigt nås från: https://edge.media-server.com/m6/p/7zkrjqvs Presentatör: Viktor Drvota, VD. För ytterligare information, vänligen kontakta : Viktor Drvota, VD, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karoli
Karolinska Development - Interim Report (January-June 2017) - Invitation to conference call and webcast24.8.2017 08:00 | Pressmeddelande
STOCKHOLM - August 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish its Interim Report - January-June 2017 on August 29, 2017 after market closure. The company will also host a conference call and an online presentation on August 30, at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: The Company will host a conference call on August 30, 2017 at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: From Sweden: +46 (0) 8 505 564 74 From the US: +1 855 753 22 30 From the UK: +44 (0) 20 336 453 74 The presentation will also be webcast and can be accessed from the following web address: https://edge.media-server.com/m6/p/7zkrjqvs Host: Viktor Drvota, CEO. For further information, please contact: Viktor Drvota, CEO, Karolinska Dev
PayByPhone Appoints Francis Dupuis as new CEO24.8.2017 01:14 | Pressmeddelande
VANCOUVER, British Columbia, Aug. 23, 2017 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it has appointed Francis Dupuis as President and Chief Executive Officer effective August 23rd, 2017. Kush Parikh, former President and CEO, has stepped down from the role after his successful 3.5-year term with the business. During his time at PayByPhone, Kush led the business to profitability, established a strong focus on end customers and was pivotal in its ground-breaking sale to Volkswagen Financial Services. "With more than 20 years of experience in the software industry and a deep product background, Francis is exactly the kind of leader we need to further grow and innovate in the parking market on an international scale," said Stefan Imme, Head of M&A and Investment Management at Volkswagen Financial Services AG. Francis, a long-standing member of the executive team at PayByPhone, takes the reins at a
Kommuniké från extra bolagsstämma i LeoVegas, 23 augusti 201723.8.2017 16:34 | Pressmeddelande
Extra bolagsstämma i LeoVegas AB (publ) ("LeoVegas" eller "Bolaget") hölls idag den 23 augusti 2017 varvid aktieägarna fattade följande beslut. Beslut om incitamentsprogram till anställda Stämman beslutade enhälligt, i enlighet med styrelsens förslag, att emittera högst 1 000 000 teckningsoptioner med avvikelse från aktieägarnas företrädesrätt till följd varav Bolagets aktiekapital kan komma att öka med högst 12 000,000022 euro. Teckningsoptionerna medför rätt till nyteckning av aktier i Bolaget. Incitamentsprogrammet ersätter det från årsstämman den 17 maj 2017 beslutade programmet i vilket samtliga teckningsoptioner makulerats efter beslut av styrelsen den 23 juli 2017 som registrerades hos Bolagsverket den 26 juli 2017. Rätt att teckna teckningsoptionerna ska tillkomma Gears of Leo AB ("Dotterbolaget") med rätt och skyldighet att, vid ett eller flera tillfäl
Announcement from LeoVegas's extra general meeting, 23 August 201723.8.2017 16:34 | Pressmeddelande
The extra general meeting ("EGM") of LeoVegas AB (publ) ("LeoVegas" or the "Company") was held today on 23 August 2017 and the following resolutions were passed. Resolution regarding incentive program for employees The EGM resolved unanimously, in accordance with the board of directors' proposal to issue a maximum of 1,000,000 warrants, with deviation from the shareholders preferential rights, which may result in a maximum increase in the Company's share capital of EUR 12,000.000022. The warrants shall entitle to subscription of new shares in the Company. The incentive program replaces the program resolved on by the annual general meeting held on 17 May 2017 in which all issued warrants have been cancelled in accordance with the board of directors resolution on 23 July 2017 which was registered with the Swedish Companies registration Office on 26 July 2017. The
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum